Related references
Note: Only part of the references are listed.Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney et al.
LANCET ONCOLOGY (2020)
ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
Cletus A. Arciero et al.
CLINICAL BREAST CANCER (2019)
30PUpdate on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
L M Smyth et al.
ANNALS OF ONCOLOGY (2019)
Prognostic Factors for Luminal B-like Breast Cancer
Nian-hua Ding et al.
CURRENT MEDICAL SCIENCE (2019)
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease
Giuseppe Viale et al.
BREAST (2019)
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Agostina Nardone et al.
BRITISH JOURNAL OF CANCER (2019)
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
Dhivya R. Sudhan et al.
CLINICAL CANCER RESEARCH (2019)
The evolving role of receptors as predictive biomarkers for metastatic breast cancer
Carlos Martinez-Perez et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
Utthara Nayar et al.
NATURE GENETICS (2019)
Crosstalk between Estrogen Signaling and Breast Cancer Metabolism
Eylem Kulkoyluoglu-Cotul et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
Real-world Treatment Patterns and Outcomes in HR+/HER2+Metastatic Breast Cancer Patients: A National Cancer Database Analysis
Abby B. Statler et al.
SCIENTIFIC REPORTS (2019)
Neoadjuvant palbociclib on ER plus breast cancer (N007): clinical response and EndoPredict's value
Louis W. C. Chow et al.
ENDOCRINE-RELATED CANCER (2018)
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients
Emanuela Risi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer
Erika P. Hamilton et al.
CLINICAL CANCER RESEARCH (2018)
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Irene L. Wapnir et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Luca Gianni et al.
LANCET ONCOLOGY (2018)
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
Hitomi Sakai et al.
BREAST CANCER (2018)
The next generation of PI3K-Akt-mTOR-pathway-inhibitors-in-breast cancer cohorts
Michael Mc Kenna et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer : a case series
Orsolya Rusz et al.
ONCOTARGETS AND THERAPY (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
Kai Zhang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
Violette Allouchery et al.
BREAST CANCER RESEARCH (2018)
Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period
Marilin Rosa et al.
BREAST JOURNAL (2018)
Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data
Sun Hyong You et al.
JOURNAL OF BREAST CANCER (2018)
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer
Lea Lowenfeld et al.
ONCOIMMUNOLOGY (2017)
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
Martina S. J. Mcdermott et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2-and ER+HER2+) breast cancers
Noriko Kanaya et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
NCCN Guidelines® Insights Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin et al.
LANCET ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Proteasome inhibitors prevent bi-directional HER2/estrogenreceptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells
Sonja Thaler et al.
ONCOTARGET (2017)
Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma
Qing-Yun Chong et al.
ONCOTARGET (2017)
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and metaanalysis of randomised controlled trials
Zhi-Qiao Xu et al.
BMJ OPEN (2017)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Xiaowei Xu et al.
CLINICAL CANCER RESEARCH (2017)
Neratinib/fulvestrant but not fulvestrant alone maintain complete responses after treatment with trastuzumab/paclitaxel of mice bearing ER+/HER2+xenografts
Luis J. Schwarz et al.
CANCER RESEARCH (2017)
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
Alexander S. Brodsky et al.
BMC CANCER (2016)
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers
Ji Hyun Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies
Laurence Lousberg et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab A Secondary Analysis of the HERA Trial
Sherene Loi et al.
JAMA ONCOLOGY (2016)
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Aleix Prat et al.
JAMA ONCOLOGY (2016)
Triple positive breast cancer: A distinct subtype?
Patrizia Vici et al.
CANCER TREATMENT REVIEWS (2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano et al.
CLINICAL CANCER RESEARCH (2015)
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer
Arran K. Turnbull et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
Donald P. McDonnell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Victoria Shang Wu et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
Betsy A. Kohler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
Betsy A. Kohler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - Moving beyond pathological complete response
Serena Di Cosimo et al.
BREAST (2014)
Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?
R. R. Saleh et al.
CURRENT ONCOLOGY (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells
Chen Yan et al.
PLOS ONE (2014)
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
I. Vaz-Luis et al.
ANNALS OF ONCOLOGY (2013)
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
F. Montemurro et al.
ANNALS OF ONCOLOGY (2013)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Nadia Harbeck et al.
BREAST CARE (2013)
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Rocio Garcia-Becerra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Debu Tripathy et al.
ONCOLOGIST (2013)
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial
J. Huober et al.
BREAST (2012)
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Rita Nahta et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
Filippo Montemurro et al.
CANCER (2012)
Poor-prognosis estrogen receptorpositive disease: present and future clinical solutions
Per E. Lonning
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
Quality of Life in Hormone Receptor-Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
Beth Sherrill et al.
ONCOLOGIST (2010)
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells
Surojeet Sengupta et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
F. Peintinger et al.
ANNALS OF ONCOLOGY (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole
William R. Miller et al.
PHARMACOGENETICS AND GENOMICS (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Does presurgical treatment destroy important prognostic information
J. Michael Dixon
BREAST CANCER RESEARCH (2007)
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
DA Berry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
G Konecny et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
PC Roche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
The development and clinical use of trastuzumab (Herceptin)
M Harries et al.
ENDOCRINE-RELATED CANCER (2002)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
